Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 7,828 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Virus Infection, RNA Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 17, 2026, 12:54 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Prevent HIV and Related Youth Health Problems

NCT05130151
View directory record Official record
Conditions
HIV Infections
Interventions
Youth Health SMS
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
15 Years to 19 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 12:54 PM EDT
Not listed No phase listed Observational

Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)

NCT05595031
View directory record Official record
Conditions
Covid 19
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

NCT00718172
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Liver Biopsy, Peginterferon & Ribavirin for Hepatitis C, Pre-treatment Ribavirin
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 2 Interventional

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

NCT00027339
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, indinavir sulfate, tenofovir disoproxil fumarate, ritonavir, fosamprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 12:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antibody Detection of Vaccine-Induced Secretory Effects

NCT04895475
View directory record Official record
Conditions
Covid19, Humoral Acquired Immunodeficiency, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2 vaccine
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

NCT00000777
View directory record Official record
Conditions
HIV Infections, Pregnancy, HIV Seronegativity
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients

NCT00002107
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

NCT00002111
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 17, 2026, 12:54 PM EDT
Terminated No phase listed Observational

User Experience of the OSR M-1

NCT04733677
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
21 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 17, 2026, 12:54 PM EDT
Completed No phase listed Observational

Behavior, Environment And Treatments for Covid-19

NCT04321811
View directory record Official record
Conditions
Coronavirus
Interventions
Observation of patients with known, suspected, or at risk for COVID-19 infection
Other
Lead sponsor
xCures
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 17, 2026, 12:54 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

NCT02118012
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Chlorcyclizine HCl, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 17, 2026, 12:54 PM EDT
Recruiting Not applicable Interventional

The Long COVID-19 Wearable Device Study

NCT05741112
View directory record Official record
Conditions
Long COVID, Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Long Covid19
Interventions
Wearable device
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 12:54 PM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

NCT00000999
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 12:54 PM EDT
Completed No phase listed Observational

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

NCT05392075
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19
Interventions
Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
Biological
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 17, 2026, 12:54 PM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Not applicable Interventional

Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

NCT00870792
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Adherence report
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Not applicable Interventional

Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV

NCT00339092
View directory record Official record
Conditions
HIV Infections
Interventions
Modified Directly Observed Therapy, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

NCT00001019
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 17, 2026, 12:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

NCT00334607
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
2-dose oral live attenuated G1P[8] human rotavirus vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 16 Weeks
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Benton, Arkansas • Cabot, Arkansas • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 17, 2026, 12:54 PM EDT